Celecoxib in Treating Patients With Bladder Cancer

Criteria: * No concurrent radiotherapy * No prior angioplasty * No concurrent chemotherapy * No concurrent oral or IV corticosteroids for more than 2 consecutive weeks or orally inhaled corticosteroids for more than 4 consecutive weeks during any 6 month period of the study * Chronic nasally inhaled steroids allowed provided patient agrees to use mometasone or, in countries where mometasone is not available, fluticasone * No prior coronary bypass surgery * At least 30 days since prior investigational medication * No other prior malignancy within the past 5 years except: * No prior pelvic radiotherapy * Histologically proven superficial transitional cell carcinoma of the bladder at high risk for recurrence, meeting 1 of the following staging criteria: * Stage Ta (grade 3 OR multifocal OR at least 2 occurrences, including current tumor, within the past 12 months) * Stage T1 (any grade) * Stage Tis * Patients with Ta or T1 lesions must have undergone complete transurethral resection of bladder tumor within the past 9 months * No carcinoma involving the prostatic urethra or upper urinary tract * Must have received the following prior to randomization: * Induction course of BCG comprising 6 weekly intravesical doses (at least 4 doses if BCG intolerant) * Additional induction courses of BCG allowed * Maintenance course of BCG comprising 3 weekly doses (at least 1 dose if BCG intolerant) * No evidence of disease by cystoscopy (with or without biopsy) and bladder cytology prior to initiation of maintenance BCG * Concurrent interferon allowed * Zubrod 0-2 or ECOG 0-2 * WBC at least 3,000/mm\^3 * Hemoglobin at least lower limit of normal * Platelet count at least 125,000/Mm\^3 * No significant bleeding disorder * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * SGOT and SGPT no greater than 1.5 times ULN * No chronic or acute hepatic disorder * Creatinine no greater than 1.5 times ULN * No chronic or acute renal disorder * Normal kidneys and ureters on imaging study within the past 9 months * No active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) * No active pancreatitis * No esophageal, gastric, pyloric channel, or duodenal ulceration that was diagnosed or treated within the past 30 days * No history of cardiovascular disease, including any of the following conditions: * Stroke * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other medical or psychological condition that would preclude study participation * No hypersensitivity or adverse reactions to sulfonamides, cyclooxygenase (COX)-2 inhibitors, salicylates, or other NSAIDs * Nonmelanomatous skin cancer cured by excision * Carcinoma in situ of the cervix * Stage 0 chronic lymphocytic leukemia * Other malignancy for which patient has no current evidence of disease, has received no therapy within the past 6 months, has no concurrent or planned therapy, and has an expected disease-free survival of at least 5 years * No concurrent immunotherapy * At least 2 weeks since prior aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) except cardioprotective dose (no greater than 100 mg/day) of aspirin * No concurrent chronic NSAIDs except oral cardioprotective dose (no greater than 100 mg/day) of aspirin * Concurrent chronic use is defined as a frequency of at least 3 times per week for more than 2 consecutive weeks per year * No other concurrent investigational drug * No other concurrent systemic therapy * No concurrent lithium or fluconazole * No other concurrent hormonal therapy except hormone replacement (i.e., estrogen or thyroid hormone replacement) * Myocardial infarction * Angina * Congestive heart failure